Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine

News provided by

Jan 28, 2026, 08:00 ET

- Nine e-posters presenting comprehensive Allergan Aesthetics portfolio data spanning first-in-class botulinum neurotoxin serotype E (TrenibotulinumtoxinE, "TrenibotE"), onabotulinumtoxinA, hyaluronic acid-based fillers and an innovative filler with biostimulatory properties
- Pooled Phase 3 efficacy, safety and patient satisfaction data for TrenibotulinumtoxinE, a first-in-class botulinum neurotoxin serotype E that delivers rapid results with a short-duration of effect
- Results from two Phase 4 studies of OnabotulinumtoxinA for Upper Facial Lines point to the benefit of long-term use and patient satisfaction with achieving natural outcomes.

IRVINE, Calif., Jan. 28, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced it will present new data from its facial aesthetics portfolio at the 2026 International Master Course on Aging Science (IMCAS) World Congress, taking place January 29–31, 2026, in Paris, France. E-posters, along with expert panels and symposiums, collectively demonstrate Allergan Aesthetics' pioneering research, new toxin innovation and commitment to advancing a multimodal approach to treatment using AA Signature™ approach.

"Allergan Aesthetics is driving the future of aesthetic medicine through a focus on scientifically driven innovation," said John Maltman, vice president, global aesthetics medical affairs, Allergan Aesthetics. "At IMCAS 2026, we're unveiling breakthrough new research that addresses patient concerns and offers health care providers new insight to on-market and emerging treatment options across neurotoxin, biostimulatory and HA filler modalities. These findings reinforce our commitment to delivering fully personalized, natural-looking outcomes using the Allergan Aesthetics facial injectable portfolio in the hands of skilled and trained clinicians."

Poster Presentations

Allergan Aesthetics will showcase data across its facial injectable portfolio and pipeline through a series of posters at IMCAS 2026 underscoring its leadership in evidence-based facial aesthetics.

Four poster presentations will showcase efficacy and safety data for TrenibotulinumtoxinE, a first-in-class botulinum neurotoxin serotype E, currently under regulatory review, that delivers rapid results with a short-duration of effect, for patients with glabellar lines.

Additional data on BOTOX^® Cosmetic highlights patient satisfaction with natural-looking results after BOTOX^® Cosmetic treatment and the benefit of long term, repeated use of BOTOX^® Cosmetic for upper facial lines.

Other poster presentations will showcase the evaluation of satisfaction and aesthetics outcomes, skin rejuvenation and a multimodal approach to treatment using AA Signature™ approach.

Title

Authors

Age-Related Efficacy Outcomes After

Treatment of Glabellar Lines With

TrenibotulinumtoxinE: A Pooled Phase 3

Subgroup Analysis

Corey Maas, Daniel P. Friedmann, Joely Kaufman-

Janette, Steve Dayan, Magdalena Boczarska-Jedynak,

Jason K. Rivers, Bryan Ho, Joan-En Lin, Maria

Musumeci, PhD, Elena Dimitrijevic

Efficacy Outcomes After Treatment With

TrenibotulinumtoxinE for Glabellar Lines in

Male Participants: A Pooled Phase 3

Subgroup Analysis

Deirdre Hooper, Rosalyn George, Terrence Keaney,

Keith Marcus, Marion Moers-Carpi, Daniela Greiner-

Krüger, Elena Dimitrijevic, Yu Guo, Joan-En Lin, Maria

Musumeci, PhD

"Novel Botulinum Neurotoxin Serotype E,

TrenibotulinumtoxinE, Delivers High

Treatment Satisfaction, Natural-looking

Results, Improved Appearance-Related

Psychological Impact for Glabellar Lines:

Patient-Reported Outcomes of a Phase 3

Randomized Trial"

Marion Moers-Carpi, Magdalena Boczarska-Jedynak,

Cheryl Burgess, Terrence Keaney, Keith Marcus, Steve

Yoelin, Tanya Brandstetter, Chung-Yi C. Chiang, Grace

S. Park, Joan-En Chang-Lin, Sandhya Shimoga

TrenibotulinumtoxinE Efficacy and Safety

for Glabellar Lines Regardless of Prior

Botulinum Toxin Use: Pooled Phase 3

Analysis

Terrence Keaney, MD; Marion Moers-Carpi, MD; Edward

Lain, MD; Cheryl Burgess, MD, FAAD; Jason Rivers, MD;

Carmen Kavali, MD; Steve Yoelin, MD; Chung-Yi C.

Chiang, PhD; Amy S. Weitzenfeld, MD^; Grace S. Park,

DrPH; Joan-En Chang-Lin, PhD

Treatment Satisfaction and Natural-

Looking Outcomes by Participant Sex:

Subgroup Findings From a Phase 4 Study

of OnabotulinumtoxinA for Upper Facial

Lines

Terrence Keaney Amir Moradi Vince Bertucci, Michael

Gold, Charles Cheng, Corey Hartman, Carmen Kavali,

Corey Maas, Alain Michon, Melissa Chiang, Tanya

Brandstetter, John Maltman, Edward Jierjian, Maria

Musumeci, PhD

Motivating Factors for Long-Term

Repeated OnabotulinumtoxinA Treatment

for Upper Facial Lines: Findings From a

Global Retrospective Chart Review and

Cross-Sectional Study

Koenraad De Boulle, MD; Amir Moradi, MD; Ligia

Colucci, MD; Ivan Tan, MD; Nowell Solish, MD; Edwin

Williams, MD; Abdullah M. Alesia, MD; Joy Diwa

Maglambayan, RPh, PMP; Tanya Brandstetter, PhD,

MSc; Teresa Zhou, PhD; John Maltman, PhD; Maria

Musumeci, PhD

An Evaluation of the Mechanism of Action

of a Hyaluronic Acid and Calcium

Hydroxyapatite Hybrid Injectable

Andre Braz, MD; Nelson Chang, MD; Fernando Urdiales-

Galves, MD; Sara Hariri, PhD; Natali Malkah, PhD;

Lauren Nakab, PharmD

An Evaluation of Satisfaction and Aesthetic

Outcomes in the Periorbital Region

Following Treatment With Hyaluronic Acid

Injectables and OnabotulinumtoxinA in the

Mid and Upper Face: A Subanalysis of

Asian Participants

Frank Lin, Samira Baharlou, Sarah Boxley, Gregory J.

Goodman, Cara McDonald, Joan Vandeputte, Ivar Van

Heijningen, Traci Baker, Carola de la Guardia

Multimodal Approaches to Skin

Rejuvenation:

From Epidermal Hydration to Dermal

Biostimulation

Françoise Boismal

The future of aesthetics: IMCAS Educational Symposia

Allergan Aesthetics will also host two symposia featuring Global experts, insights, panel discussions and live injection sessions, designed to explore patient needs and enhance clinical practice:

Global Medical Affairs symposium: The Heritage and Future of Botulinum Toxin: Next Generation Toxin and Expanding Horizons on Friday, 30 January, 08:30.
- Will explore new developments in the toxins space, the long-term patient journey and the drive for natural outcomes.
- Session led by Dr. Natalie Rajaonarivelo and features Dr. Patricia Ogilvie, Dr. Daniela Greiner-Krüger, Dr. Vince Bertucci and Dr. Koenraad De Boulle.
The Allergan Medical Institute (AMI) Symposium: 'AA Signature™: When patients' aspirations meet clinical reality on Friday, 30 January, 14:00.
- Focuses on transformative strategies using the Allergan Aesthetics portfolio and AA Signature™ approach to treatment, combined with real-world applications and expert insights.
- The session will be led by Dr. Sylwia Lipko-Godlewska and Dr. Marcel Vinicius and features Professor Sebastian Cotofana and Dr. Mustafa Narwan.

Representatives from Allergan Aesthetics will also participate in multiple scientific events and Think Tanks, including an Industry Tribune featuring conversation on trends around the combination use of aesthetic products.

Delegates can also visit the Allergan Aesthetics booth and Global Aesthetics Medical Affairs booth – E130 – to explore the interactive AMI product injection experience, learn more about Allergan Aesthetics' advanced portfolio through AA Signature™, and connect with experts to learn more about the science behind the portfolio.

Notes to editors:
AA Signature
AA Signature™ is a multimodal portfolio-based approach to treatment that integrates Allergan Aesthetics' leading products, AMI training, and services to deliver a personalized treatment approach, whether patients are looking for lift, more definition or improved skin quality.

BOTOX^® Cosmetic (onabotulinumtoxinA) Important Information

Indications

BOTOX^® Cosmetic (onabotulinumtoxinA) is indicated in adult patients for the temporary improvement in the appearance of:
- Moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity
- Moderate to severe lateral canthal lines associated with orbicularis oculi activity
- Moderate to severe forehead lines associated with frontalis activity
- Moderate to severe platysma bands associated with platysma muscle activity

IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of BOTOX^® Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses.

CONTRAINDICATIONS
BOTOX^® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.

WARNINGS AND PRECAUTIONS
Lack of Equivalency Between Botulinum Toxin Products
The potency Units of BOTOX^® Cosmetic are specific to the preparation and assay method utilized. BOTOX^® Cosmetic is not equivalent to other preparations of botulinum toxin products, and therefore, Units of biological activity of BOTOX^® Cosmetic cannot be compared to nor converted into Units of any other botulinum toxin products assessed with any other specific assay method.

Spread of Toxin Effect
Please refer to Boxed Warning for Distant Spread of Toxin Effect.

No definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX^® Cosmetic at the labeled dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines), 40 Units (for forehead lines with glabellar lines), 44 Units (for simultaneous treatment of lateral canthal lines and glabellar lines), and 64 Units (for simultaneous treatment of lateral canthal lines, glabellar lines, and forehead lines) have been reported. Patients or caregivers should be advised to seek immediate medical care if swallowing, speech, or respiratory disorders occur.

Serious Adverse Reactions With Unapproved Use
Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some adverse reactions associated with fatal outcomes, have been reported in patients who received BOTOX^® injections for unapproved uses. In these cases, the adverse reactions were not necessarily related to distant spread of toxin, but may have resulted from the administration of BOTOX^® to the site of injection and/or adjacent structures. In several of the cases, patients had preexisting dysphagia or other significant disabilities. There is insufficient information to identify factors associated with an increased risk for adverse reactions associated with the unapproved uses of BOTOX^®. The safety and effectiveness of BOTOX^® for unapproved uses have not been established.

Hypersensitivity Reactions
Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea. If such a reaction occurs, discontinue further injection of BOTOX Cosmetic and immediately institute appropriate medical therapy. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent and, consequently, the causal agent cannot be reliably determined.

Cardiovascular System
There have been reports following administration of BOTOX^® of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors, including preexisting cardiovascular disease. Use caution when administering to patients with preexisting cardiovascular disease.

Increased Risk of Clinically Significant Effects With Preexisting Neuromuscular Disorders
Patients with neuromuscular disorders may be at increased risk of clinically significant effects, including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise from onabotulinumtoxinA (see Warnings and Precautions). Monitor individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis or neuromuscular junction disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) when given botulinum toxin.

Dysphagia and Breathing Difficulties
Treatment with BOTOX^® and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with preexisting swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or oropharyngeal muscles that control swallowing or breathing (see Boxed Warning).

Preexisting Conditions at the Injection Site
Use caution when BOTOX^® Cosmetic treatment is used in the presence of inflammation at the proposed injection site(s) or when excessive weakness or atrophy is present in the target muscle(s).

Dry Eye in Patients Treated With BOTOX^® Cosmetic
There have been reports of dry eye associated with BOTOX^® Cosmetic injection in or near the orbicularis oculi muscle. If symptoms of dry eye (eg, eye irritation, photophobia, or visual changes) persist, consider referring patients to an ophthalmologist.

Human Albumin and Transmission of Viral Diseases
This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries a remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), which would also be considered remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

ADVERSE REACTIONS
The most frequently reported adverse reactions following injection of BOTOX^® Cosmetic for glabellar lines were eyelid ptosis (3%), facial pain (1%), facial paresis (1%), and muscular weakness (1%).

The most frequently reported adverse reaction following injection of BOTOX^® Cosmetic for lateral canthal lines was eyelid edema (1%).

The most frequently reported adverse reactions following injection of BOTOX^® Cosmetic for forehead lines with glabellar lines were headache (9%), brow ptosis (2%), and eyelid ptosis (2%).

The safety profile of BOTOX^® Cosmetic treatment of platysma bands is consistent with the known safety profile of BOTOX^® Cosmetic for other indications.

DRUG INTERACTIONS
Coadministration of BOTOX^® Cosmetic and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. Use of anticholinergic drugs after administration of BOTOX^® Cosmetic may potentiate systemic anticholinergic effects.

The effect of administering different botulinum neurotoxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of BOTOX^® Cosmetic.

USE IN SPECIFIC POPULATIONS
There are no studies or adequate data from postmarketing surveillance on the developmental risk associated with use of BOTOX^® Cosmetic in pregnant women. There are no data on the presence of BOTOX^® Cosmetic in human or animal milk, the effects on the breastfed child, or the effects on milk production.

Please see BOTOX^® Cosmetic full Prescribing Information, including Boxed Warning and Medication Guide.

SKINVIVE by JUVÉDERM^® Injectable Gel Important Information

INDICATIONS
SKINVIVE by JUVÉDERM^® injectable gel is indicated for intradermal injection to improve skin smoothness of the cheeks in adults over the age of 21.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: Not for patients with a history of anaphylaxis, presence of multiple severe allergies, or allergies to Gram-positive bacterial proteins or lidocaine in this product.

WARNINGS: Do not inject into blood vessels as this may lead to embolization, occlusion of the vessels, ischemia, or infarction. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits changes in vision, signs of a stroke, blanching of the skin, or unusual pain during or shortly after the procedure. Patients should receive prompt medical attention should an intravascular injection occur. Treatment at specific sites should be deferred where there is an active inflammatory process or infection.

PRECAUTIONS: Only healthcare professionals who have appropriate training, experience, and are knowledgeable of the anatomy at and around the injection site should use this product. As with all transcutaneous procedures, injections carry a risk of infection. The safety for use during pregnancy, breastfeeding, and in patients with known susceptibility to keloid formation, hypertrophic scarring, or pigmentation disorders has not been established. Use with caution in patients on immunosuppressive therapy. Patients taking medications that can prolong bleeding may experience increased bruising or bleeding at treatment sites. Patients may experience late onset AEs with use of injectable gel implants, including SKINVIVE by JUVÉDERM^®

ADVERSE EVENTS: The most commonly reported injection site responses included redness, lumps/bumps, swelling, bruising, pain, tenderness, firmness, discoloration, and itching. Most were mild, lasting 7 days or less.

Please see Directions for Use or visit SKINVIVE.com for more information.

SKINVIVE by JUVÉDERM^® is available only by a licensed physician or properly licensed practitioner.

The investigational products described above, TrenibotulinumtoxinE for the treatment of glabellar lines and SKINVIVE by JUVÉDERM^® for the improvement of neck appearance, have not yet been shown to be safe and effective for their intended uses.

About Allergan Aesthetics

At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter) and YouTube.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Media:

Adelle Infante

[email protected]

Investors:

Liz Shea

[email protected]

SOURCE AbbVie